UBS Group AG Sells 256,313 Shares of Taysha Gene Therapies, Inc. $TSHA

UBS Group AG lowered its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 40.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 383,043 shares of the company’s stock after selling 256,313 shares during the quarter. UBS Group AG owned 0.14% of Taysha Gene Therapies worth $2,107,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Taysha Gene Therapies in the third quarter valued at about $40,000. Marex Group plc acquired a new position in Taysha Gene Therapies in the second quarter valued at about $29,000. E Fund Management Co. Ltd. acquired a new position in Taysha Gene Therapies in the second quarter valued at about $31,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Taysha Gene Therapies by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,311 shares of the company’s stock valued at $73,000 after buying an additional 2,765 shares in the last quarter. Finally, Allegheny Financial Group acquired a new position in Taysha Gene Therapies in the third quarter valued at about $49,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Price Performance

Shares of TSHA stock opened at $5.75 on Thursday. Taysha Gene Therapies, Inc. has a 1 year low of $2.25 and a 1 year high of $7.30. The firm’s 50 day moving average is $5.46 and its 200-day moving average is $5.05. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -15.13 and a beta of 1.25. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Sell-side analysts forecast that Taysha Gene Therapies, Inc. will post -0.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on TSHA shares. Truist Financial upgraded shares of Taysha Gene Therapies to a “strong-buy” rating in a research report on Wednesday, March 25th. Chardan Capital restated a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Needham & Company LLC upped their target price on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th. Finally, Wall Street Zen lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $11.64.

Insider Activity

In related news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the completion of the sale, the insider directly owned 1,136,410 shares of the company’s stock, valued at $5,068,388.60. The trade was a 14.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.78% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.